Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo

Iizuka,Kenzo; Zhang,Chun; Eshima,Kokoro; Jin,Cheng; Eshima,Kiyoshi; Fukushima,Masakazu

doi:10.3892/ijo.2018.4246

Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo

Authors:
- Kenzo Iizuka
- Chun Zhang
- Kokoro Eshima
- Cheng Jin
- Kiyoshi Eshima
- Masakazu Fukushima
View Affiliations

Affiliations: Division of Oncology Research and Development, Delta-Fly Pharma Inc., Kawauchi-cho, Tokushima 771-0116, Japan
Published online on: January 16, 2018 https://doi.org/10.3892/ijo.2018.4246
Pages: 851-860

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofranocylcytosine (DFP-10917, CNDAC) is a 2'-deoxycytidine analog with antitumor activity against various tumor cells. However, a clinically available therapeutic regimen for this compound needs to be established and its functional mechanisms in relation to the dosing schedule need to be clarified. In this study, we evaluated the antitumor activity and toxicity of DFP-10917 by varying the dose and administration schedule in human solid tumor and leukemia xenografts in vivo. Compared to a 1-day infusion with a high-dose of DFP-10917 (30 mg/kg/day), a prolonged 14-day infusion with a low-dose (4.5 mg/kg/day) exerted superior tumor growth inhibitory effects without decreasing the body weights of mice in our human tumor xenograft model. In addition, we found that a 14-day infusion of low-dose DFP-10917 markedly prolonged the lifespan of nude mice bearing both acute leukemia and ovarian cancer cell-derived tumors. On the other hand, gemcitabine (GEM) and cytosine arabinoside (Ara-C), which are similar deoxycytidine analogs and are widely used clinically as standard regimens, exerted less potent antitumor effects than DFP-10917 on these tumors. To elucidate the possible functional mechanisms of the prolonged infusion of DFP-10197 compared with that of GEM or Ara-C, the rate of DNA damage in CCRF-CEM and HeLa cells treated with DFP-10917, Ara-C and GEM was detected using a comet assay. DFP-10917, at a range of 0.05 to 1 µM, induced a clear tailed-DNA pattern in both the CCRF-CEM and HeLa cells; Ara-C and GEM did not have any effect. It was thus suggested that a low concentration and long-term exposure to DFP-10917 aggressively introduced the fragmentation of DNA molecules, namely the so-called double-strand breaks in tumor cells, leading to potent cytotoxicity. Moreover, treatment with DFP-10917 at a low-dose with a long-term exposure specifically increased the population of cells in the G2/M phase, while GEM reduced this cell population, suggesting a unique function (G2/M arrest) of DFP-10917. On the whole, our findings indicate that the prolonged infusion of low-dose DFP-10917 mainly displays a novel functional mechanism as a DNA-damaging drug and may thus prove to be useful in the treatment of cancer patients who are resistant to other cytosine nucleosides, or in patients in which these other nucleosides have been shown to be ineffective.

View Figures

View References

1	Noble S and Goa KL: Gemcitabine A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 54:447–472. 1997. View Article : Google Scholar : PubMed/NCBI
2	Barton-Burke M: Gemcitabine: A pharmacologic and clinical overview. Cancer Nurs. 22:176–183. 1999. View Article : Google Scholar : PubMed/NCBI
3	Toschi L, Finocchiaro G, Bartolini S, Gioia V and Cappuzzo F: Role of gemcitabine in cancer therapy. Future Oncol. 1:7–17. 2005. View Article : Google Scholar
4	Cole N and Gibson BE: High-dose cytosine arabinoside in the treatment of acute myeloid leukaemia. Blood Rev. 11:39–45. 1997. View Article : Google Scholar : PubMed/NCBI
5	Kern W and Estey EH: High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer. 107:116–124. 2006. View Article : Google Scholar : PubMed/NCBI
6	Reese ND and Schiller GJ: High-dose cytarabine (HD araC) in the treatment of leukemias: A review. Curr Hematol Malig Rep. 8:141–148. 2013. View Article : Google Scholar : PubMed/NCBI
7	Li W, Gong X, Sun M, Zhao X, Gong B, Wei H, Mi Y and Wang J: High-dose cytarabine in acute myeloid leukemia treatment: A systematic review and meta-analysis. PLoS One. 9:e1101532014. View Article : Google Scholar : PubMed/NCBI
8	Somasekaram A, Jarmuz A, How A, Scott J and Navaratnam N: Intracellular localization of human cytidine deaminase. Identification of a functional nuclear localization signal. J Biol Chem. 274:28405–28412. 1999. View Article : Google Scholar : PubMed/NCBI
9	Azuma A, Nakajima Y, Nishizono N, Minakawa N, Suzuki M, Hanaoka K, Kobayashi T, Tanaka M, Sasaki T and Matsuda A: Nucleosides and nucleotides. 122 2′-C-cyano-2′-deoxy-1-β-D-arabinofuranosylcytosine and its derivatives A new class of nucleoside with a broad antitumor spectrum. J Med Chem. 36:4183–4189. 1993. View Article : Google Scholar : PubMed/NCBI
10	Azuma A, Hanaoka K, Kurihara A, Kobayashi T, Miyauchi S, Kamo N, Tanaka M, Sasaki T and Matsuda A: Nucleosides and nucleotides. 141. Chemical stability of a new antitumor nucleoside, 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine in alkaline medium: Formation of 2′-C-cyano-2′-deoxy-1-β-D-ribo-pentofuranosylcytosine and its antitumor activity. J Med Chem. 38:3391–3397. 1995. View Article : Google Scholar : PubMed/NCBI
11	Tanaka M, Matsuda A, Terao T and Sasaki T: Antitumor activity of a novel nucleoside, 2′-C-cyano-2′-deoxy-1-β-D-arabinofuranosylcytosine (CNDAC) against murine and human tumors. Cancer Lett. 64:67–74. 1992. View Article : Google Scholar : PubMed/NCBI
12	Azuma A, Huang P, Matsuda A and Plunkett W: Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC). Biochem Pharmacol. 61:1497–1507. 2001. View Article : Google Scholar : PubMed/NCBI
13	Hayakawa Y, Kawai R, Otsuki K, Kataoka M and Matsuda A: Evidence supporting the activity of 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentafuranosylcytosine as a terminator in enzymatic DNA-chain elongation. Bioorg Med Chem Lett. 8:2559–2562. 1998. View Article : Google Scholar
14	Azuma A, Huang P, Matsuda A and Plunkett W: 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine: A novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. Mol Pharmacol. 59:725–731. 2001. View Article : Google Scholar : PubMed/NCBI
15	Liu X, Guo Y, Li Y, Jiang Y, Chubb S, Azuma A, Huang P, Matsuda A, Hittelman W and Plunkett W: Molecular basis for G2 arrest induced by 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation. Cancer Res. 65:6874–6881. 2005. View Article : Google Scholar : PubMed/NCBI
16	Wang Y and Liu X: M<atsuda A and Plunkett W: Repair of 2′-C-cyano-2′-deoxy-1-β-D-arabino-pantofuranosylcytosine-induced DNA single-starand breaks by transcription-coupled nucleotide excision repair. Cancer Res. 68:3881–2889. 2008. View Article : Google Scholar : PubMed/NCBI
17	Liu X, Wang Y, Benaissa S, Matsuda A, Kantarjian H, Estrov Z and Plunkett W: Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. Blood. 116:1737–1746. 2010. View Article : Google Scholar : PubMed/NCBI
18	Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51:6110–6117. 1991.PubMed/NCBI
19	Jiang HY, Hickey RJ, Abdel-Aziz W and Malkas LH: Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome. Cancer Chemother Pharmacol. 45:320–328. 2000. View Article : Google Scholar
20	Miura S and Izuta S: DNA polymerases as targets of anticancer nucleosides. Curr Drug Targets. 5:191–195. 2004. View Article : Google Scholar : PubMed/NCBI
21	Liao W, McNutt MA and Zhu WG: The comet assay: A sensitive method for detecting DNA damage in individual cells. Methods. 48:46–53. 2009. View Article : Google Scholar : PubMed/NCBI
22	Food and Drug Administration HHS: HHS International conference on harmonisation; guidance on S9 nonclincal evaluation for anticancer pharmaceuticals; availability. Fed Regist. 75:10487–10488. 2010.
23	Cook N, Hansen AR, Siu LL and Abdul Razak AR: Early phase clinical trials to identify optimal dosing and safety. Mol Oncol. 9:997–1007. 2015. View Article : Google Scholar :
24	Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
25	Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, et al: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 18:122–130. 2000. View Article : Google Scholar : PubMed/NCBI
26	Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R and Mackey JR: The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res. 10:6956–6961. 2004. View Article : Google Scholar : PubMed/NCBI
27	Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH, Yang PC and Ho CC1: Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer. 59:105–110. 2008. View Article : Google Scholar
28	Veerman G, Ruiz van Haperen VW, Vermorken JB, Noordhuis P, Braakhuis BJ, Pinedo HM and Peters GJ: Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol. 38:335–342. 1996. View Article : Google Scholar
29	Kirstein MN, Wieman KM, Williams BW, Fisher JE, Marker PH, Le CT, Yee D and Kratzke RA: Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system. Lung Cancer. 58:196–204. 2007. View Article : Google Scholar : PubMed/NCBI
30	Rajdev L, Goldberg G, Hopkins U and Sparano JA: A phase I trial of gemcitabine administered as a 96-h continuous intravenous infusion in patients with advanced carcinoma and lymphoma. Med Oncol. 23:369–376. 2006. View Article : Google Scholar : PubMed/NCBI
31	Tempero M, Plunkett W, Ruiz Van, Haperen V, Hainsworth J, Hochster H, Lenzi R and Abbruzzese J: Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 21:3402–3408. 2003. View Article : Google Scholar : PubMed/NCBI
32	Cappuzzo F, Novello S, De Marinis F, Selvaggi G, Scagliotti GV, Barbieri F, Maur M, Papi M, Pasquini E, Bartolini S, et al: A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer. 52:319–325. 2006. View Article : Google Scholar : PubMed/NCBI
33	Ho DH, Brown NS, Benvenuto J, McCredie KB, Buckels D and Freireich EJ: Pharmacologic studies of continuous infusion of arabinosylcytosine by liquid infusion system. Clin Pharmacol Ther. 22:371–374. 1977. View Article : Google Scholar : PubMed/NCBI
34	Kreis W, Chaudhri F, Chan K, Allen S, Budman DR, Schulman P, Weiselberg L, Freeman J, Deere M and Vinciguerra V: Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days. Cancer Res. 45:6498–6501. 1985.PubMed/NCBI
35	Spriggs DR, Robbins G, Takvorian T and Kufe DW: Continuous infusion of high-dose 1-beta-D-arabinofuranosylcytosine: A phase I and pharmacological study. Cancer Res. 45:3932–3936. 1985.PubMed/NCBI
36	Donehower RC, Karp JE and Burke PJ: Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep. 70:1059–1065. 1986.PubMed/NCBI
37	Spriggs DR, Sokal JE, Griffin J and Kufe DW: Low-dose ara-C administered by continuous subcutaneous infusion: A pharmacologic evaluation. Cancer Drug Deliv. 3:211–216. 1986. View Article : Google Scholar : PubMed/NCBI
38	Bolwell BJ, Cassileth PA and Gale RP: Low-dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: A review. Leukemia. 1:575–579. 1987.PubMed/NCBI
39	Stentoft J: The toxicity of cytarabine. Drug Saf. 5:7–27. 1990. View Article : Google Scholar : PubMed/NCBI
40	Stone RM, Spriggs DR, Dhawan RK, Arthur KA, Mayer RJ and Kufe DW: A phase I study of intermittent continuous infusion high-dose cytosine arabinoside for acute leukemia. Leukemia. 4:843–847. 1990.PubMed/NCBI
41	Schiller G, Gajewski J, Nimer S, Territo M, Ho W, Lee M and Champlin R: A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. Br J Haematol. 81:170–177. 1992. View Article : Google Scholar : PubMed/NCBI
42	Fleming RA, Capizzi RL, Rosner GL, Oliver LK, Smith SJ, Schiffer CA, Silver RT, Peterson BA, Weiss RB, Omura GA, et al: Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: A cancer and leukemia group B study. Cancer Chemother Pharmacol. 36:425–430. 1995. View Article : Google Scholar : PubMed/NCBI
43	Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, et al: A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 87:1710–1717. 1996.PubMed/NCBI
44	Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, et al Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group: Cytarabine dose for acute myeloid leukemia. N Engl J Med. 364:1027–1036. 2011. View Article : Google Scholar : PubMed/NCBI